论文部分内容阅读
目的:探讨骨髓增生异常综合征(MDS)患者骨髓组织中类胰酶阳性的肥大细胞表达水平。方法:用骨髓塑料冷包埋技术结合免疫组织化学的方法检测10例健康供者,8例IDA患者、20例MDS(11例低危组,9例高危组)、17例急性髓性白血病(AML)患者骨髓类胰酶阳性的肥大细胞的数量,并作对比分析。结果:IDA组(63.43±44.29)与健康供者的类胰酶阳性肥大细胞数(61.43±56.19)类似(P值>0.05)。MDS组(195.95±117.39)较健康供者类胰酶阳性的肥大细胞数增多(P值<0.05)。MDS高危组(229.25±139.68)较低危组(171.73±98.07)高,但无统计学差异(P值>0.05));AML组(608.44±342.58)较MDS组明显增多(P值<0.01)。各组类胰酶阳性肥大细胞数与外周血常规、骨髓原始粒细胞数、嗜酸性粒细胞数、嗜碱性粒细胞数无相关性。结论:MDS和AML患者骨髓组织中均存在类胰酶阳性肥大细胞数目异常增多现象,它可能在MDS的病理发生发展中起一定作用。
Objective: To investigate the expression of trypan blue-positive mast cells in bone marrow of patients with myelodysplastic syndrome (MDS). Methods: 10 cases of healthy donors, 8 cases of IDA, 20 cases of MDS (11 cases of low risk group and 9 cases of high risk group) and 17 cases of acute myeloid leukemia (ALL) were treated with bone marrow cryostomy and immunohistochemistry AML) in patients with bone marrow trypanase-positive mast cells, and for comparative analysis. Results: The IDA group (63.43 ± 44.29) was similar to that of pancreatic positive mast cells (61.43 ± 56.19) in healthy donors (P> 0.05). MDS group (195.95 ± 117.39) than healthy donors positive pancreatic enzyme-positive mast cells increased (P value <0.05). MDS group (229.25 ± 139.68) was higher than the low-risk group (171.73 ± 98.07), but there was no significant difference (P> 0.05); The AML group (608.44 ± 342.58) . The number of pancreatic enzyme-positive mast cells in each group had no correlation with the routine blood routine, the number of primitive myeloid cells, the number of eosinophils and the number of basophils in peripheral blood. Conclusion: The abnormal increase of pancreatic enzyme positive mast cells in both MDS and AML patients may play a role in the pathological development of MDS.